RxDoctor Payments DataLook up a doctor →

Paul Cook, MD

Infectious Disease · Greenville, NCNPI 1760482970

Payments from drug & device makers

$2,913,054in general payments, 2019–2025

Across 349 payments — averaging $8346.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.5M
  • Janssen Research & Development, LLC$544K
  • Gilead$382K
  • AbbVie$200K
  • Merck$117K
  • Viiv Healthcare Company$71K
  • plus $89K from 17 others
$1,710in research payments, 2019–2025

Across 12 payments — averaging $142.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$1K
  • Eli Lilly$378

What the payments were for

  • Consulting fees$6555%
  • Travel & lodging$11,20183%
  • Food & beverage$1,46611%
  • Education$811%
  • Gifts$881%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,913,054 in reported general payments places this provider in the 95th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,229
Medicare patients
165
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala210$818,482
TivicayDolutegravir Sodium187$408,171
PrezcobixDarunavir/Cobicistat156$375,305
DovatoDolutegravir Sodium/Lamivudine93$248,107
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$234,937
OdefseyEmtricitab/Rilpiviri/Tenof Ala46$150,316
TriumeqAbacavir/Dolutegravir/Lamivudi25$96,473
OzempicSemaglutide15$13,724
JanuviaSitagliptin Phosphate13$12,025
BelsomraSuvorexant12$4,766
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid18$3,871
Lamivudine-ZidovudineLamivudine/Zidovudine20$2,122
AbacavirAbacavir Sulfate12$1,604
ValacyclovirValacyclovir Hcl18$947
Ethambutol Hcl13$932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$382,266$818,482210 claims
Viiv Healthcare CompanyTivicay, Dovato, Triumeq$71,038$752,750305 claims
Johnson & JohnsonPrezcobix$106$375,305156 claims
Janssen Products, LPSymtuza$30$234,93747 claims
MerckJanuvia, Belsomra$116,949$16,79225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →